Ms. Rosemarie Gene Ells, 5201003961 Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 745 Water Tower Rd, Big Rapids, MI 49307 Phone: 231-592-1061 Fax: 231-592-5139 |
Mrs. Rebecca Lynn Brinks, OTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 605 Oak St, Big Rapids, MI 49307 Phone: 231-592-4453 |
Ms. Cynthia Ann Johnstone, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 745 Water Tower Rd, Big Rapids, MI 49307 Phone: 231-592-1061 Fax: 231-592-5139 |
Devyn Dean Powell I, OTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 605 Oak St, Big Rapids, MI 49307 Phone: 231-878-5205 |
Molly Laskowski Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 805 West Ave, Big Rapids, MI 49307 Phone: 231-796-3185 |
News Archive
Researchers at Mayo Clinic have completed the world's first whole exome sequence of small intestine neuroendocrine tumors, also known to patients and physicians as carcinoids, the most common cancer of the small bowel and one that responds poorly to chemotherapy.
Many neurological disorders, such as Parkinson's disease and Alzheimer's disease, are marked by impaired motor skills. In addition, growing evidence suggests there's a link between some neurodegenerative diseases and body weight. A recent NIH study, for example, found that adults who are obese or overweight at midlife may be at risk for earlier onset of Alzheimer's disease.
A new Johns Hopkins Medicine analysis of national trauma data shows that trauma patients were four times more likely to die from gunshot wounds and nearly nine times more likely to die from stab wounds before getting to a trauma center in 2014, compared with rates in 2007.
The time since a stroke need not determine when patients undergo elective coronary artery bypass grafting, say researchers.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.
› Verified 9 days ago